Rezolute reports third quarter fiscal 2024 financial results and provides business update

Patient enrollment underway in sunrize global phase 3 clinical study of rz358 in patients with congenital hyperinsulinism (chi); topline results expected in mid-2025

RZLT Ratings Summary

RZLT Quant Ranking